|Day Low/High||19.00 / 19.95|
|52 Wk Low/High||11.93 / 24.85|
Investors in AMAG Pharmaceuticals, Inc. saw new options begin trading this week, for the November 16th expiration.
NDA includes data from two successful Phase 3 trials in HSDD in premenopausal women in which bremelanotide met the pre-specified co-primary efficacy endpoints
Investors in AMAG Pharmaceuticals, Inc. saw new options become available this week, for the April 20th expiration.
Marks Second FDA Approval for AMAG this Month; Company to File NDA for Bremelanotide, A Novel Women's Health Product, Later this Quarter
Feraheme is Now a Treatment Option for All Eligible Adult Patients with Iron Deficiency Anemia
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AMAG Pharmaceuticals, Inc. , where a total volume of 4,588 contracts has been traded thus far today, a contract volume which is representative of approximately 458,800 underlying shares (given that every 1 contract represents 100 underlying shares).
Patent designed to protect the subcutaneous administration of Makena(R) (hydroxyprogesterone caproate injection)
Palatin to Receive $500,000 Upfront
More than one-third of study participants in Phase 2 Study were Cord Blood Registry® (CBR®) clients
Investors eyeing a purchase of AMAG Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $17.50/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Prescription Drug User Fee Act (PDUFA) Target Action Date of February 2, 2018 Established
The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,611,369 share decrease in total short interest for AMAG Pharmaceuticals, Inc. , to 8,685,429, a decrease of 15.65% since 07/31/2017.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.